Analysts Offer Insights on Healthcare Companies: Amgen Inc (NASDAQ: AMGN) and Amarin (NASDAQ: AMRN)

By Carrie Williams

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amgen Inc (AMGNResearch Report) and Amarin (AMRNResearch Report) with bullish sentiments.

Amgen Inc (AMGN)

In a report released today, Salim Syed from Mizuho Securities assigned a Buy rating to Amgen Inc, with a price target of $208. The company’s shares closed yesterday at $192.11.

According to TipRanks.com, Syed is a 2-star analyst with an average return of 0.5% and a 49.0% success rate. Syed covers the Healthcare sector, focusing on stocks such as Unity Biotechnology Inc, Atara Biotherapeutics, and Wave Life Sciences.

Currently, the analyst consensus on Amgen Inc is a Moderate Buy with an average price target of $215.82, a 12.3% upside from current levels. In a report issued on April 3, Oppenheimer also maintained a Buy rating on the stock with a $224 price target.

See today’s analyst top recommended stocks >>

Amarin (AMRN)

In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Amarin, with a price target of $35. The company’s shares closed yesterday at $18.79.

Chen noted:

“We think the peak sales potential of Vascepa is underappreciated. Therefore, upward earnings revisions to levels not reflected in FactSet consensus expectations should drive AMRN shares higher. Valuation Summary We continue to use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $35.”

According to TipRanks.com, Chen is a 5-star analyst with an average return of 12.6% and a 47.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Amneal Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.

Currently, the analyst consensus on Amarin is a Strong Buy with an average price target of $38.67, implying a 105.8% upside from current levels. In a report issued on March 28, Jefferies also maintained a Buy rating on the stock with a $30 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.